The CCKA receptor antagonist SR 27897 differentially influences the activity of A9 and A10 dopaminergic neurons in the rat.
Santucci
V
V
Department of Neuropsychiatry, Sanofi Recherche, Montpellier, France.
Gueudet
C
C
Thurneyssen
O
O
Gully
D
D
Soubrie
P
P
Le Fur
G
G
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology; D020109:Devazepide; D004298:Dopamine / Q000378:metabolism*; D007210:Indoleacetic Acids / Q000494:pharmacology*; D008297:Male; D008636:Mesencephalon / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D012844:Sincalide / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D001570:Benzodiazepinones; D007210:Indoleacetic Acids; D011949:Receptors, Cholecystokinin; D013844:Thiazoles; C080460:SR 27897; D020109:Devazepide; D012844:Sincalide; D001058:Apomorphine; D004298:Dopamine